Napoleone Ferrara
University of California, San Diego
Vascular endothelial growth factor CCancerEndothelial stem cellInternal medicineEndocrinologyPathologyVascular endothelial growth factor AVascular endothelial growth factor BMolecular biologyReceptorChemistryImmunologyGrowth factorEndotheliumVascular endothelial growth factorNeovascularizationAngiogenesisCancer researchMedicineBiologyCell biology
371Publications
179H-index
125kCitations
Publications 362
Newest
#1Marco Mura (UHN: University Health Network)H-Index: 19
#2Matthew Binnie (U of T: University of Toronto)H-Index: 15
Last. Mingyao Liu (U of T: University of Toronto)H-Index: 97
view all 12 authors...
Vascular endothelial growth factor-A (VEGF) is a potent regulator of vascular permeability, inflammatory response, and cell survival in the lung. To explore the functions of VEGF produced locally in type II pneumocytes, we generated mice with a conditional deletion of VEGF-A using Cre recombinase driven by the human surfactant protein C (SPC) promoter. In 7- to 10-week-old VEGF-knockout (SPC-VEGF-KO) mice, lung histology and physiology were essentially normal, except for higher dynamic lung comp...
31 CitationsSource
#1Seth B. Coffelt (University of Sheffield)H-Index: 28
#2Claire E. Lewis (University of Sheffield)H-Index: 82
Last. Michele De Palma (UniSR: Vita-Salute San Raffaele University)H-Index: 54
view all 6 authors...
It is now established that bone marrow–derived myeloid cells regulate tumor angiogenesis. This was originally inferred from studies of human tumor biopsies in which a positive correlation was seen between the number of tumor-infiltrating myeloid cells, such as macrophages and neutrophils, and tumor microvessel density. However, unequivocal evidence was only provided once mouse models were used to examine the effects on tumor angiogenesis by genetically or pharmacologically targeting myeloid cell...
163 CitationsSource
PURPOSE OF REVIEW: Targeting the vascular endothelial growth factor (VEGF) pathway has had a significant impact in the therapy of cancer and intraocular neovascular disorders. Similar to other therapies, inherent/acquired resistance to anti-VEGF drugs may occur in cancer patients, leading to disease recurrence. This review describes recent findings on the role of myeloid cells in refractoriness or/and acquired resistance to such therapies. RECENT FINDINGS: Various myeloid cell types, including t...
152 CitationsSource
Vascular endothelial growth factor (VEGF, VEGF-A) is a major regulator of physiological and pathological angiogenesis. One feature of VEGF is the existence of multiple isoforms arising from alternative exon splicing. Our initial biochemical and biological studies indicated that such isoforms are uniquely suited to generate angiogenic gradients by virtue of their differential ability to interact with the extracellular matrix (ECM). Although ECM-bound VEGF was bioactive, processing by physiologica...
238 CitationsSource
#1Nathalie Ortega (UCSF: University of California, San Francisco)H-Index: 7
#2Ke WangH-Index: 3
Last. Thiennu H. VuH-Index: 24
view all 5 authors...
SUMMARY Long bone development depends on endochondral bone formation, a complex process requiring exquisite balance between hypertrophic cartilage (HC) formation and its ossification. Dysregulation of this process may result in skeletal dysplasias and heterotopic ossification. Endochondral ossification requires the precise orchestration of HC vascularization, extracellular matrix remodeling, and the recruitment of osteoclasts and osteoblasts. Matrix metalloproteinase-9 (MMP-9), vascular endothel...
109 CitationsSource
FDA approval of several inhibitors of the VEGF pathway has enabled significant advances in the therapy of cancer and neovascular age-related macular degeneration. However, similar to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in patients, leading to disease progression. So far the lack of predictive biomarkers has precluded identification of patients most likely to respond to such treatments. Recent suggest that both tumor and non-tumor (stromal) cell types ...
331 CitationsSource
Although most cancer therapies are directed against tumor cells, an emerging area of cancer therapeutics focuses on targeting cells of the tumor microenvironment. Inhibiting the Src family kinase with dasatinib decreases tumor growth through inhibiting growth of tumor-associated endothelial and myeloid cells. Clin Cancer Res; 16(3); 775–7
8 CitationsSource
#1Beate M. Lichtenberger (Medical University of Vienna)H-Index: 15
#2Poi Kiang Tan (Medical University of Vienna)H-Index: 1
Last. Maria Sibilia (Medical University of Vienna)H-Index: 45
view all 6 authors...
It is established that tumor cell-derived VEGF acts on endothelial cells to promote angiogenesis and tumor growth. Here, we demonstrate that in K5-SOS-dependent mouse skin tumors, autocrine VEGF is required for tumor cell proliferation in a cell-autonomous and angiogenesis-independent manner. VEGF is upregulated in SOS-expressing tumors, and its deletion in epidermal cells delays tumorigenesis by suppressing angiogenesis and tumor cell proliferation. Epidermis-specific Flt1 deletion also impairs...
348 CitationsSource
#1Bob Y. Liu (Genentech)H-Index: 5
#2Irina Soloviev (Genentech)H-Index: 5
Last. Chie Sakanaka (Genentech)H-Index: 3
view all 9 authors...
Background Histological examinations of MMTV-Wnt1 tumors reveal drastic differences in the tumor vasculature when compared to MMTV-Her2 tumors. However, these differences have not been formally described, nor have any angiogenic factors been implicated to be involved in the Wnt1 tumors. Methodology/Principal Findings Here, we show that MMTV-Wnt1 tumors were more vascularized than MMTV-Her2 tumors, and this correlated with significantly higher expression of a CXC chemokine, stromal cell-derived f...
27 CitationsSource
#1Napoleone FerraraH-Index: 179
#2Yongping CrawfordH-Index: 15
1 CitationsSource